|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DPH5 |
Gene summary for DPH5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DPH5 | Gene ID | 51611 |
| Gene name | diphthamide biosynthesis 5 | |
| Gene Alias | AD-018 | |
| Cytomap | 1p21.2 | |
| Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | B3KWP1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51611 | DPH5 | LZE4T | Human | Esophagus | ESCC | 5.83e-07 | 1.14e-01 | 0.0811 |
| 51611 | DPH5 | LZE7T | Human | Esophagus | ESCC | 3.82e-05 | 1.63e-01 | 0.0667 |
| 51611 | DPH5 | LZE20T | Human | Esophagus | ESCC | 5.71e-05 | 7.37e-02 | 0.0662 |
| 51611 | DPH5 | LZE24T | Human | Esophagus | ESCC | 9.84e-03 | 8.84e-02 | 0.0596 |
| 51611 | DPH5 | P1T-E | Human | Esophagus | ESCC | 2.73e-03 | 9.67e-02 | 0.0875 |
| 51611 | DPH5 | P2T-E | Human | Esophagus | ESCC | 1.68e-17 | 2.90e-01 | 0.1177 |
| 51611 | DPH5 | P4T-E | Human | Esophagus | ESCC | 2.02e-18 | 2.89e-01 | 0.1323 |
| 51611 | DPH5 | P5T-E | Human | Esophagus | ESCC | 1.38e-09 | 1.19e-01 | 0.1327 |
| 51611 | DPH5 | P8T-E | Human | Esophagus | ESCC | 1.01e-12 | 8.90e-02 | 0.0889 |
| 51611 | DPH5 | P9T-E | Human | Esophagus | ESCC | 2.13e-11 | 1.07e-01 | 0.1131 |
| 51611 | DPH5 | P10T-E | Human | Esophagus | ESCC | 2.00e-22 | 2.14e-01 | 0.116 |
| 51611 | DPH5 | P12T-E | Human | Esophagus | ESCC | 6.29e-33 | 5.70e-01 | 0.1122 |
| 51611 | DPH5 | P15T-E | Human | Esophagus | ESCC | 2.57e-07 | 1.84e-01 | 0.1149 |
| 51611 | DPH5 | P16T-E | Human | Esophagus | ESCC | 2.30e-25 | 1.85e-01 | 0.1153 |
| 51611 | DPH5 | P17T-E | Human | Esophagus | ESCC | 5.82e-07 | 2.01e-01 | 0.1278 |
| 51611 | DPH5 | P20T-E | Human | Esophagus | ESCC | 1.20e-14 | 1.82e-01 | 0.1124 |
| 51611 | DPH5 | P21T-E | Human | Esophagus | ESCC | 9.27e-19 | 9.52e-02 | 0.1617 |
| 51611 | DPH5 | P22T-E | Human | Esophagus | ESCC | 7.22e-22 | 2.78e-01 | 0.1236 |
| 51611 | DPH5 | P23T-E | Human | Esophagus | ESCC | 3.70e-24 | 4.11e-01 | 0.108 |
| 51611 | DPH5 | P24T-E | Human | Esophagus | ESCC | 1.06e-11 | 1.11e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
| GO:000641419 | Esophagus | ESCC | translational elongation | 41/8552 | 55/18723 | 1.26e-05 | 1.16e-04 | 41 |
| GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
| GO:000641712 | Liver | Cirrhotic | regulation of translation | 194/4634 | 468/18723 | 7.28e-16 | 8.79e-14 | 194 |
| GO:000218122 | Liver | HCC | cytoplasmic translation | 132/7958 | 148/18723 | 9.09e-33 | 5.76e-30 | 132 |
| GO:000641722 | Liver | HCC | regulation of translation | 287/7958 | 468/18723 | 8.79e-17 | 8.08e-15 | 287 |
| GO:0032259 | Liver | HCC | methylation | 206/7958 | 364/18723 | 3.35e-08 | 7.53e-07 | 206 |
| GO:000641412 | Liver | HCC | translational elongation | 36/7958 | 55/18723 | 4.94e-04 | 3.23e-03 | 36 |
| GO:000218120 | Oral cavity | OSCC | cytoplasmic translation | 133/7305 | 148/18723 | 1.94e-38 | 2.46e-35 | 133 |
| GO:000641720 | Oral cavity | OSCC | regulation of translation | 274/7305 | 468/18723 | 4.39e-18 | 4.63e-16 | 274 |
| GO:000641416 | Oral cavity | OSCC | translational elongation | 37/7305 | 55/18723 | 2.03e-05 | 1.94e-04 | 37 |
| GO:00322591 | Oral cavity | OSCC | methylation | 168/7305 | 364/18723 | 3.03e-03 | 1.31e-02 | 168 |
| GO:0002181110 | Oral cavity | LP | cytoplasmic translation | 124/4623 | 148/18723 | 5.09e-52 | 3.19e-48 | 124 |
| GO:0006417110 | Oral cavity | LP | regulation of translation | 175/4623 | 468/18723 | 4.49e-10 | 2.22e-08 | 175 |
| GO:000641417 | Oral cavity | LP | translational elongation | 25/4623 | 55/18723 | 6.27e-04 | 5.71e-03 | 25 |
| GO:000218129 | Skin | cSCC | cytoplasmic translation | 127/4864 | 148/18723 | 4.83e-53 | 7.57e-50 | 127 |
| GO:000641729 | Skin | cSCC | regulation of translation | 226/4864 | 468/18723 | 8.78e-26 | 2.62e-23 | 226 |
| GO:000641423 | Skin | cSCC | translational elongation | 30/4864 | 55/18723 | 6.13e-06 | 8.70e-05 | 30 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DPH5 | SNV | Missense_Mutation | novel | c.353G>A | p.Gly118Asp | p.G118D | Q9H2P9 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DPH5 | SNV | Missense_Mutation | c.272N>G | p.His91Arg | p.H91R | Q9H2P9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DPH5 | SNV | Missense_Mutation | novel | c.610N>A | p.Gln204Lys | p.Q204K | Q9H2P9 | protein_coding | tolerated(0.57) | benign(0) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DPH5 | SNV | Missense_Mutation | novel | c.777N>G | p.Ile259Met | p.I259M | Q9H2P9 | protein_coding | tolerated(0.35) | benign(0.003) | TCGA-A5-A7WJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DPH5 | SNV | Missense_Mutation | novel | c.95N>T | p.Glu32Val | p.E32V | Q9H2P9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| DPH5 | SNV | Missense_Mutation | novel | c.141G>T | p.Glu47Asp | p.E47D | Q9H2P9 | protein_coding | tolerated(0.23) | benign(0.02) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| DPH5 | SNV | Missense_Mutation | novel | c.10C>A | p.Leu4Ile | p.L4I | Q9H2P9 | protein_coding | tolerated(0.39) | benign(0.033) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| DPH5 | SNV | Missense_Mutation | novel | c.290N>T | p.Arg97Ile | p.R97I | Q9H2P9 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| DPH5 | SNV | Missense_Mutation | c.476N>T | p.Thr159Ile | p.T159I | Q9H2P9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D1-A17D-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| DPH5 | SNV | Missense_Mutation | novel | c.618N>G | p.Ile206Met | p.I206M | Q9H2P9 | protein_coding | tolerated(0.11) | benign(0) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |